LabGenius Therapeutics
PrivateLast Round
Series B
Extension
Feb 16, 2026
Total Funding Raised
$78.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
LabGenius Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series B Extension round in February 2026.
LabGenius Therapeutics is a biotechnology company that develops an AI-driven protein engineering platform to discover and optimize next-generation therapeutic antibodies for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, ML Platforms
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LabGenius Therapeutics Comparables
Compare LabGenius Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BigHat Biosciences | 89% | |
| Nabla Bio | 86% | |
| Earendil Labs | 85% |
For institutional investors. Book with your work email.
LabGenius Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Feb 16, 2026 | ||||
| Series B | May 21, 2024 | ||||
| Grant | Nov 30, 2022 | ||||
| Grant | Oct 7, 2022 | ||||
| Series A Extension | Oct 29, 2020 | ||||
Series A | Oct 24, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LabGenius Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Backed VC | Seed |
| Beast Mode | Seed |
| System.One | Seed |
| Inovia Capital | Series A, Series A Extension |
| Air Street Capital | Series A |
| Gaingels | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 95% MoM, reaching 4.2K.
- Apr 25, 2026
Monthly visitors increased 180% MoM, reaching 3.1K.
For institutional investors. Book with your work email.
LabGenius Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LabGenius Therapeutics's valuation, stock price, and market status.
Is LabGenius Therapeutics a public or private company?
LabGenius Therapeutics is a private company.
What is the current stock price of LabGenius Therapeutics?
LabGenius Therapeutics is a private company, so its shares have no public market price. Caplight tracks LabGenius Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LabGenius Therapeutics worth (valuation)?
Valuation information for LabGenius Therapeutics is not publicly available.
Can I buy LabGenius Therapeutics stock?
LabGenius Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LabGenius Therapeutics's last funding round?
LabGenius Therapeutics's most recent funding round was Series B Extension on February 16, 2026.
Who are the main investors in LabGenius Therapeutics?
Key investors in LabGenius Therapeutics include Acequia Capital, M Ventures, Lux Capital, Obvious Ventures, Innovate UK.
Will LabGenius Therapeutics IPO soon?
No public IPO plans have been announced for LabGenius Therapeutics.
How can I track LabGenius Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in LabGenius Therapeutics's shares on secondary markets.